Nemtabrutinib is an investigational medication being studied for its potential to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is being compared to other treatments to see how well it works in improving the overall response rate and progression-free survival in patients who have not been treated before.

Ibrutinib is a medication used to treat certain types of blood cancers, including chronic lymphocytic leukemia (CLL). It works by blocking a specific protein that helps cancer cells grow and survive. In this study, it is used as a comparator to evaluate the effectiveness of nemtabrutinib.

Acalabrutinib is another medication used to treat chronic lymphocytic leukemia (CLL). Similar to ibrutinib, it targets a protein that is important for the growth and survival of cancer cells. In this trial, it serves as a comparator to assess how well nemtabrutinib performs in treating the disease.

Small Lymphocytic Lymphoma (SLL) – This is a type of cancer that affects the lymphocytes, which are a kind of white blood cell. It is closely related to chronic lymphocytic leukemia (CLL) and often considered the same disease, differing mainly in where the cancer cells are found. In SLL, the cancer cells are primarily located in the lymph nodes, whereas in CLL, they are mostly in the blood and bone marrow. The disease progresses slowly, and symptoms may include swollen lymph nodes, fatigue, and night sweats. Over time, it can affect the body’s ability to fight infections.

Chronic Lymphocytic Leukemia (CLL) – This is a type of cancer that starts in the bone marrow and affects the blood, specifically targeting the lymphocytes. It is characterized by the slow accumulation of abnormal lymphocytes in the blood, bone marrow, and lymphoid tissues. CLL progresses gradually and may not cause symptoms for years. As it advances, it can lead to symptoms such as fatigue, swollen lymph nodes, and frequent infections. The disease can eventually interfere with the production of normal blood cells.